About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Genomic Profiling to Identify the Best Therapy for Bladder Cancer

by Ramya Rachamanti on May 10, 2019 at 6:20 PM
Font : A-A+

Genomic Profiling to Identify the Best Therapy for Bladder Cancer

Genomic underpinnings of various differences among patients with muscle invasive bladder cancer were studied by Lerner and his colleagues at Baylor. They reported a comprehensive molecular characterization of 412 muscle-invasive bladder cancers as part of the Cancer Genome Atlas Research Network group. This resulted in the identification of five expression-based cancer subtypes with distinct survival outcomes in 2017. One of the subtypes named 'neuronal' has a very distinct expression profile and is associated with poor survival and less favorable outcomes.

"One of the challenges that we have when taking care of patients with bladder cancer is that from one patient to the next, the prognosis, the stage and the response to different kinds of treatment differ," said Dr. Seth Paul Lerner, who is the director of urologic oncology and of the Multidisciplinary Bladder Cancer Program as well as professor of urology and Beth and Dave Swalm Chair in Urologic Oncology at Baylor College of Medicine. "The diverse cancer characteristics pose a challenge when selecting the best treatment for each patient."

Advertisement


"We were able to show that mutation signatures, molecular subtypes, load of new cancer-associated molecules and known clinical and pathological factors have a very clear influence on overall patient survival," Lerner said. "But, how can we apply this knowledge into clinical practice?"

"In this study published in European Urology in 2019, we report the development of a computational tool - a single-patient classifier - that effectively enables physicians to assign a bladder cancer subtype to an individual patient's cancer using that patient's genomic data," said first author Dr. Jaegil Kim, who was at the Broad Institute at the time he was working on this project and currently is a senior principal scientist in TESARO, an oncology-focused company.
Advertisement

The researchers also applied their single-patient classifier to the data produced by the IMvigor 210 clinical trials that treated nearly 400 patients with locally advanced or metastatic bladder cancer with atezolizumab, a type of immunotherapy drug, and reported objective response and overall survival. This enabled the researchers to connect response to treatment with a particular bladder cancer subtype.

"One of the most exciting findings is that the aggressive neuronal expression subtype we had identified in 2017 as having poor survival and less favorable outcome responds very well to atezolizumab treatment and patients have a much better outcome," Kim said.

"Of the 11 patients we identified as having a neuronal subtype, all of those evaluable for objective response responded to the treatment (two complete response, six partial response), or 72 percent overall. This translated to a very high survival probability which is unprecedented in advanced bladder cancer," Lerner said. "Although this is a small group of patients, it is very exciting to see that our basic research can be directly translated to the clinical setting allowing us to determine which subtype of bladder cancer has a better chance to respond well to a specific treatment.

" Although further testing is needed in prospective clinical trials, the researchers anticipate a future in which a physician can apply the single-patient classifier to patients' tumor genomic data to identify the subtype of bladder cancer, and then select the treatment the particular subtype is most likely to respond to.

"Bladder cancer causes an estimated 160,000 deaths worldwide per year and we are behind other cancer fields in terms of the clinical applications of its molecular data and biology," Lerner said. "However, we can begin to see how we can use this information in the future to provide the best treatment for each patient."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Ten Fruits for Diabetics
Natural Supplements Help Reverse Hair Loss during Menopause
Ways to Manage Stress during COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Vesico-Ureteric Reflux Causing UTI in Children Enuresis/Bedwetting Reiki and Pranic Healing Cancer Facts Cancer Tattoos A Body Art Interstitial Cystitis Bladder Cancer Common Lifestyle Habits that Cause Diseases 

Recommended Reading
Decipher Test for Prostate Cancer
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer .....
Bladder Cancer
Bladder cancer occurs due to abnormal cell growth in the urinary bladder. The most common kind usual...
Common Lifestyle Habits that Cause Diseases
Cigarette smoking, unhealthy diets, overuse of alcohol, and physical inactivity are some of the most...
Enuresis/Bedwetting
Bedwetting (nocturnal enuresis) is involuntary voiding of urine during sleep at least three times a ...
Interstitial Cystitis
Interstitial cystistis is an umbrella term where a pathology cannot be defined but the patient suf...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...
Vesico-Ureteric Reflux Causing UTI in Children
Bacterial infection of urinary bladder can cause pain and burning sensation while passing urine. Abn...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use